Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66
   PubMed Web of Science ®Google Scholar
• Alexanian R, Haut A, Khan A U, Lane M, McKelvey E M, Migliore P J, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680–1685
   PubMed Web of Science ®Google Scholar
• Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol 1998; 16: 3832–3842
   PubMedGoogle Scholar
• Facon T, Mary J, Hulin C, Benboubker L, Attal M, Renaud M, et al. Major Superiority of melphalan − prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood (Suppl.) 2005; 106: 780
   Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825–831
   PubMed Web of Science ®Google Scholar
• San Miguel J F, Garcia-Sanz R, Gonzalez M, Orfao A. Immunophenotype and DNA cell content in multiple myeloma. Baillieres Clin Haematol 1995; 8: 735–759
   PubMed Web of Science ®Google Scholar
• San Miguel J F, Gonzalez M, Gascon A, Moro M J, Hernandez J M, Ortega F, et al. Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol 1991; 77: 185–190
   PubMed Web of Science ®Google Scholar
• Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp M J, et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 2003; 102: 1070–1071
   PubMed Web of Science ®Google Scholar
• Treon S P, Pilarski L M, Belch A R, Kelliher A, Preffer F I, Shima Y, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002; 25: 72–81
   PubMed Web of Science ®Google Scholar
• Zojer N, Kirchbacher K, Vesely M, Hubl W, Ludwig H. Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leuk Lymphoma 2006; 47: 1103–1109
   PubMed Web of Science ®Google Scholar
• Cook J R, Hsi E D, Worley S, Tubbs R R, Hussein M. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival. Am J Clin Pathol 2006; 125: 615–624
   PubMed Web of Science ®Google Scholar
• Pilarski L M, Jensen G S. Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. Hematol Oncol Clin North Am 1992; 6: 297–322
   PubMed Web of Science ®Google Scholar
• Bergsagel P, Smith A, Szczepek A, Mant M, Belch A, Pilarski L. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 1995; 85: 436–447, Erratum at 85:3365
   PubMed Web of Science ®Google Scholar
• Moreau P, Voillat L, Benboukher L, Mathiot C, Dumontet C, Robillard N, et al. Rituximab in CD20 positive multiple myeloma. Leukemia 2007; 21: 835–836
   PubMed Web of Science ®Google Scholar
• Jacobson J L, Hussein M A, Barlogie B, Durie B G, Crowley J J. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 2003; 122: 441–450
   PubMed Web of Science ®Google Scholar
• Greipp P R, Leong T, Bennett J M, Gaillard J P, Klein B, Stewart J A, et al. Plasmablastic morphology – an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 1998; 91: 2501–2507
   PubMed Web of Science ®Google Scholar
• Treon S P, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-Cell malignancies. J Immunother 2001; 24: 263–271
   PubMed Web of Science ®Google Scholar
• Musto P, Carella A M, Jr, Greco M M, Falcone A, Sanpaolo G, Bodenizza C, et al. Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation. Br J Haematol 2003; 123: 746–747
   PubMed Web of Science ®Google Scholar